Psychological Treatment Trials for Hypoactive Sexual Desire Disorder: A Sexual Medicine Critique and Perspective

Journal of Sexual Medicine

Volumn 12, Issue 12, 2015, Pages 2451-2458

  Pyke, Robert E ^a   Clayton, Anita H ^b  

^a Medical Department   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Clinical Significance; Cognitive Behavior Therapy; Control Treatment Paradigm; Female Sexual Dysfunction; Hypoactive Sexual Desire Disorder; Mindfulness Meditation

Indexed keywords

CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DEROGATIS SEXUAL FUNCTION INVENTORY; GENITAL SYSTEM DISEASE ASSESSMENT; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; MINDFULNESS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; REVIEW; RISK BENEFIT ANALYSIS; SEXUAL AROUSAL; SEXUAL BEHAVIOR; SEXUAL FUNCTION; ADULT; FEMALE; LIBIDO; PSYCHOLOGY; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

ADULT; COGNITIVE THERAPY; FEMALE; HUMANS; LIBIDO; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 84947810109     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.13056     Document Type: Article

References (42)

1. Fineout-Overholt E, Hofstetter S, Shell L, Johnston L. Teaching EBP: Getting to the gold: How to search for the best evidence. Worldviews Evid Based Nurs 2005;2:207-211.
2. England MJ, Butler AE, Gonzalez ML, eds. Psychosocial interventions for mental and substance use disorders: A framework for establishing evidence-based standards. Washington, DC: Institute of Medicine; 2015.
3. FDA. Patient-focused drug development public meeting and scientific workshop on female sexual dysfunction, 2014 October 28th Scientific Workshop, Meeting Recording, FDA.gov.
4. FDA. Clinical background document for the Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and Drug Safety and Risk Management (DSaRM) Advisory Committee, June 4, 2015, Flibanserin, Division of Bone, Reproductive and Urologic Products, Office of Drug Evaluation III, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, May 8, 2015.
5. Sand M, Thorp J, Jolly E, Garcia M. How well do measures of sexual function correlate with patients' perspectives of improvement in HSDD? J Sex Med 2010;7(suppl 4):169.
6. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987;22:141-173.
7. DeRogatis LR, Edelson J, Jordan R, Greenberg S, Portman DJ. Bremelanotide for female Sexual dysfunctions: Responder analyses from a phase 2B dose-ranging study, 62nd Annual Clinical Meeting of the American College of Obstetricians and Gynecologists, April 26-30, 2014, Available at: http://www.palatin.com/pdfs/PAL%20P4027%20ACOG%20DeRogatis%20Responder%20Analysis%20Poster%200421-2.pdf (accessed September 14, 2015).
8. Boehringer Ingelheim. Briefing document, flibanserin tablet, 14 May 2010.
9. FDA. Background document for meeting of advisory committee for reproductive health drugs: Flibanserin, May 20, 2010.
10. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): Cross-validation and development of clinical cutoff scores. J Sex Marital Ther 2006;13:46-56.
11. Clayton AH, Segraves RT, Bakish D, Goldmeier D, Tignol J, van Lunsen RH, Nappi RE, Wunderlich G, Kimura T, Lewis-D'Agostino DJ, Pyke R. Cutoff score of the sexual interest and desire inventory-female for diagnosis of hypoactive sexual desire disorder. J Womens Health (Larchmt) 2010;19:2191-2195.
12. Gerstenberger EP, Rosen RC, Brewer JV, Meston CM, Brotto LA, Wiegel M, Sand M. Sexual desire and the female sexual function index (FSFI): A sexual desire cutpoint for clinical interpretation of the FSFI in women with and without hypoactive sexual desire disorder. J Sex Med 2010;7:3096-3103.
13. Jones LM, McCabe MP. The effectiveness of an internet-based psychological treatment program for female sexual dysfunction. J Sex Med 2011;8:2781-2792.
14. Hucker A, McCabe MP. Incorporating mindfulness and chat groups into an online cognitive behavioral therapy for mixed female sexual problems. J Sex Res 2015;52:627-639.
15. Brotto LA, Erskine Y, Carey M, Ehlen T, Finlayson S, Heywood M, Kwon J, McAlpine J, Stuart G, Thomson S, Miller D. A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer. Gynecol Oncol 2012;125:320-325.
16. Brotto LA, Basson R. Group mindfulness-based therapy significantly improves sexual desire in women. Behav Res Ther 2014;57:43-54.
17. DeRogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J. The Female Sexual Distress Scale (FSDS): Initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther 2002;28:317-330.
18. Clayton AH, Edelson J, Jordan R, Effect of self-administered bremelanotide on sexual interest and desire in premenopausal women with sexual dysfunctions, Presented at the 167th Annual Meeting of the American Psychiatric Association, May 3-7, 2014, New York, Available at: http://www.palatin.com/pdfs/PAL%20P4077%20APA%20Clayton%20SIDF-F%20All%20Domains-Items%20Poster%200421-1.pdf (accessed September 14, 2015).
19. Trudel G, Marchand A, Ravart M, Aubin S, Turgeon L, Fortier P. The effect of a cognitive-behavioral group treatment program on hypoactive sexual desire in women. Sex Relat Ther 2001;16:145-164.
20. DeRogatis LR, Synopsis of the DeRogatis sexual functioning inventory (DSFI). 2015 Available at: http://www.derogatis-tests.com/dsfi_synopsis.asp (accessed September 14, 2015).
21. Guenzler C, Berner MM. Efficacy of psychosocial interventions in men and women with sexual dysfunctions-A systematic review of controlled clinical trials, part 2-The efficacy of psychosocial interventions for female sexual dysfunction. J Sex Med 2012;9:3108-3125.
22. Hurlbert DF. A comparative study using orgasm consistency training in the treatment of women reporting hypoactive sexual desire. J Sex Marital Ther 1993;19:41-55.
23. Fruehauf S, Gerger H, Schmidt HM, Munder T, Barth J. Efficacy of psychological interventions for sexual dysfunction: A systematic review and meta-analysis. Arch Sex Behav 2013;42:915-933.
24. Macphee DC, Johnson SM, van Der Veer MMC. Low sexual desire in women: The effects of marital therapy. J Sex Marital Ther 1995;21:159-182.
25. Hucker A, McCabe MP. An online, mindfulness-based, cognitive-behavioral therapy for female sexual difficulties: Impact on relationship functioning. J Sex Marital Ther 2014;40:561-576.
26. McCabe MP. Evaluation of a cognitive behavior therapy program for people with sexual dysfunction. J Sex Marital Ther 2001;27:259-271.
27. Brotto LA, Krychman M, Jacobson P. Eastern approaches for enhancing women's sexuality: Mindfulness, acupuncture, and yoga (CME). J Sex Med 2008;5:2741-2748.
28. Brotto LA, Heiman JR, Goff B, Greer B, Lentz GM, Swisher E, Tamimi H, Van Blaricom A. A psychoeducational intervention for sexual dysfunction in women with gynecologic cancer. Arch Sex Behav 2008;37:317-329.
29. Brotto LA, Basson R, Luria M. A mindfulness-based group psychoeducational intervention targeting sexual arousal disorder in womaen. J Sex Med 2008;5:1646-1659.
30. Hucker A, McCabe MP. Manualized treatment programs for FSD: Research challenges and recommendations. J Sex Med 2012;9:350-360.
31. Sealed Envelope Ltd, Exmouth House, 3/11 Pine Street, London EC1R 0JH, UK. Available at: https://www.sealedenvelope.com/power/continuous-superiority/ (accessed accessed September 14, 2015).
32. Derogatis LR, Komer L, Katz M, Moreau M, Kimura T, Garcia M Jr, Wunderlich G, Pyke R, VIOLET Trial Investigators. Treatment of hypoactive sexual desire disorder in premenopausal women: Efficacy of flibanserin in the VIOLET study. J Sex Med 2012;9:1074-1085.
33. Thorp J, Simon J, Dattani D, Taylor L, Kimura T, Garcia M Jr, Lesko L, Pyke R. DAISY trial investigators, treatment of hypoactive sexual desire disorder in premenopausal women: Efficacy of flibanserin in the DAISY study. J Sex Med 2012;9:793-804.
34. Schramm E, Hautzinger M, Zobel I, Kriston L, Berger M, Haerter M. Comparative efficacy of the cognitive behavioral analysis system of psychotherapy versus supportive psychotherapy for early onset chronic depression: Design and rationale of a multisite randomized controlled trial. BMC Psychiatry 2011;11:134.
35. Hofmann SG, Asnaani A, Vonk IJJ, Sawyer AT, Fang A. The efficacy of cognitive behavioral therapy: A review of meta-analyses. Cognit Ther Res 2012;36:427-440.
36. Smith PN, Gamble SA, Cort NA, Ward EA, He H, Talbot NL. Attachment and alliance in the treatment of depressed, sexually abused women. Depress Anxiety 2012;29:123-130.
37. Quirk K, Owen J, Inch LJ, France T, Bergen C. The alliance in relationship education programs. J Marital Fam Ther 2014;40:178-192.
38. Scope A, Leaviss J, Kaltenthaler E, Parry G, Sutcliffe P, Bradburn M, Cantrell A. Is group cognitive behaviour therapy for postnatal depression evidence-based practice? A systematic review. BMC Psychiatry 2013;13:321.
39. Williams JM, Crane C, Barnhofer T, Brennan K, Duggan DS, Fennell MJ, Hackmann A, Krusche A, Muse K, Von Rohr IR, Shah D, Crane RS, Eames C, Jones M, Radford S, Silverton S, Sun Y, Weatherley-Jones E, Whitaker CJ, Russell D, Russell IT. Mindfulness-based cognitive therapy for preventing relapse in recurrent depression: A randomized dismantling trial. J Consult Clin Psychol 2014;82:275-286.
40. Espie CA, Kyle SD, Miller CB, Ong J, Hames P, Fleming L. Attribution, cognition and psychopathology in persistent insomnia disorder: Outcome and mediation analysis from a randomized placebo-controlled trial of online cognitive behavioural therapy. Sleep Med 2014;15:913-917.
41. Flückiger C, Del Re AC, Wampold BE, Symonds D, Horvath AO. How central is the alliance in psychotherapy? A multilevel longitudinal meta-analysis. J Couns Psychol 2012;59:10-17.
42. Fabre LF, Clayton AH, Smith LC, Goldstein I, Derogatis LR. The effect of gepirone-ER in the treatment of sexual dysfunction in depressed men. J Sex Med 2012;9:821-829.